Impact of Covid-19 on Rhinovirus Epidemic (IPCoRV)

April 26, 2022 updated by: Hospices Civils de Lyon

Impact of Covid-19 Pandemic on the Epidemiology of Rhinovirus

Rhinovirus (RV) has long been known as the main etiological agent of "common colds" among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring.

The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (NPI).

However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 2 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France

- Positive rhinovirus-PCR

Description

Inclusion Criteria:

  • - Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France
  • Positive rhinovirus-PCR

Exclusion Criteria:

  • - parent's refusal to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pre Covid 19 cohort
Infants hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2019 to 16th March 2020.
Other: epidemiology
To review medical records to describe diagnosis and severity of the disease.
Other Names:
  • Medical record analysis
Other: epidemiology
To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
Other Names:
  • Comparison of cohorts
Per Covid 19 cohort year 1
Infant hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2020 to 16th March 2021. The need to recruit patients for an additional per-covid year (from 17th March 2021 to 16th March 2022) will be evaluated after the data from the first 2 years of recruitment are available.
Other: epidemiology
To review medical records to describe diagnosis and severity of the disease.
Other Names:
  • Medical record analysis
Other: epidemiology
To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
Other Names:
  • Comparison of cohorts
Per Covid 19 cohort, year 2
Infants hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for Rhinovirus from 17th March 2021 to 16th March 2022. The need to recruit patients for this additional cohort will be evaluated after the data from the first 2 years of recruitment are available and analyzed.
Other: epidemiology
To review medical records to describe diagnosis and severity of the disease.
Other Names:
  • Medical record analysis
Other: epidemiology
To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
Other Names:
  • Comparison of cohorts

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of pre Covid-19 pandemic.
Time Frame: From one year before the SARS-CoV-2 pandemic until the beginning of the SARS-CoV-2 pandemic
Description of number of clinical picture cases for pre-SARS-CoV-2 pandemic year.
From one year before the SARS-CoV-2 pandemic until the beginning of the SARS-CoV-2 pandemic
Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of per-Covid-19 pandemic.
Time Frame: From the beginning of the SARS-CoV-2 pandemic until one year latter
Description of number of clinical picture cases for per-SARS-CoV-2 pandemic year.
From the beginning of the SARS-CoV-2 pandemic until one year latter

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

May 1, 2022

Primary Completion (Anticipated)

April 1, 2023

Study Completion (Anticipated)

May 1, 2023

Study Registration Dates

First Submitted

February 17, 2022

First Submitted That Met QC Criteria

April 26, 2022

First Posted (Actual)

April 27, 2022

Study Record Updates

Last Update Posted (Actual)

April 27, 2022

Last Update Submitted That Met QC Criteria

April 26, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 502_2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rhinovirus

Clinical Trials on epidemiology

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe